DIFLUPREDNATE by Exelan Pharmaceuticals, Inc. / Cipla USA Inc. / Farmabios S.p.A. DIFLUPREDNATE emulsion

DIFLUPREDNATE by

Drug Labeling and Warnings

DIFLUPREDNATE by is a Prescription medication manufactured, distributed, or labeled by Exelan Pharmaceuticals, Inc., Cipla USA Inc., Farmabios S.p.A.. Drug facts, warnings, and ingredients follow.

Drug Details [pdf]

  • 1 INDICATIONS AND USAGE

    1.1 Ocular Surgery

    Difluprednate ophthalmic emulsion 0.05%, a topical corticosteroid, is indicated for the treatment of inflammation and pain associated with ocular surgery.

    1.2 Endogenous Anterior Uveitis

    Difluprednate ophthalmic emulsion is also indicated for the treatment of endogenous anterior uveitis.

  • 2 DOSAGE AND ADMINISTRATION

    2.1 Ocular Surgery

    Instill one drop into the conjunctival sac of the affected eye 4 times daily beginning 24 hours after surgery and continuing throughout the first 2 weeks of the postoperative period, followed by 2 times daily for a week and then a taper based on the response.

    2.2 Endogenous Anterior Uveitis

    Instill one drop into the conjunctival sac of the affected eye 4 times daily for 14 days followed by tapering as clinically indicated.

  • 3 DOSAGE FORMS AND STRENGTHS

    Difluprednate ophthalmic emulsion contains 0.05% difluprednate as a sterile preserved emulsion for topical ophthalmic administration.

  • 4 CONTRAINDICATIONS

    The use of difluprednate ophthalmic emulsion, as with other ophthalmic corticosteroids, is contraindicated in most active viral diseases of the cornea and conjunctiva including epithelial herpes simplex keratitis (dendritic keratitis), vaccinia, and varicella, and also in mycobacterial infection of the eye and fungal disease of ocular structures.

  • 5 WARNINGS AND PRECAUTIONS

    5.1 IOP Increase

    Prolonged use of corticosteroids may result in glaucoma with damage to the optic nerve, defects in visual acuity and fields of vision. Steroids should be used with caution in the presence of glaucoma. If this product is used for 10 days or longer, intraocular pressure should be monitored.

    5.2 Cataracts

    Use of corticosteroids may result in posterior subcapsular cataract formation.

    5.3 Delayed Healing

    The use of steroids after cataract surgery may delay healing and increase the incidence of bleb formation. In those diseases causing thinning of the cornea or sclera, perforations have been known to occur with the use of topical steroids. The initial prescription and renewal of the medication order beyond 28 days should be made by a physician only after examination of the patient with the aid of magnification such as slit lamp biomicroscopy and, where appropriate, fluorescein staining.

    5.4 Bacterial Infections

    Prolonged use of corticosteroids may suppress the host response and thus increase the hazard of secondary ocular infections. In acute purulent conditions, steroids may mask infection or enhance existing infection. If signs and symptoms fail to improve after 2 days, the patient should be re-evaluated.

    5.5 Viral Infections

    Employment of a corticosteroid medication in the treatment of patients with a history of herpes simplex requires great caution. Use of ocular steroids may prolong the course and may exacerbate the severity of many viral infections of the eye (including herpes simplex).

    5.6 Fungal Infections

    Fungal infections of the cornea are particularly prone to develop coincidentally with long-term local steroid application. Fungus invasion must be considered in any persistent corneal ulceration where a steroid has been used or is in use. Fungal culture should be taken when appropriate.

    5.7 Topical Ophthalmic Use Only

    Difluprednate ophthalmic emulsion is not indicated for intraocular administration.

    5.8 Contact Lens Wear

    Difluprednate ophthalmic emulsion should not be instilled while wearing contact lenses. Remove contact lenses prior to instillation of difluprednate ophthalmic emulsion. The preservative in difluprednate ophthalmic emulsion may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of difluprednate ophthalmic emulsion.

  • 6 ADVERSE REACTIONS

    The following serious reactions are found elsewhere in the labeling:

    • Elevated intraocular pressure [see Warnings and Precautions (5.1)]
    • Posterior subcapsular cataract formation [see Warnings and Precautions (5.2)]
    • Secondary ocular infection [see Warnings and Precautions (5.4)]
    • Perforation of the globe [see Warnings and Precautions (5.3)]

    6.1 Ocular Surgery

    Ocular adverse reactions occurring in 5-15% of subjects in clinical studies with difluprednate included corneal edema, ciliary and conjunctival hyperemia, eye pain, photophobia, posterior capsule opacification, anterior chamber cells, anterior chamber flare, conjunctival edema, and blepharitis. Other ocular adverse reactions occurring in 1-5% of subjects included reduced visual acuity, punctate keratitis, eye inflammation, and iritis. Ocular adverse reactions occurring in < 1% of subjects included application site discomfort or irritation, corneal pigmentation and striae, episcleritis, eye pruritis, eyelid irritation and crusting, foreign body sensation, increased lacrimation, macular edema, sclera hyperemia, and uveitis. Most of these reactions may have been the consequence of the surgical procedure.

    6.2 Endogenous Anterior Uveitis

    A total of 200 subjects participated in the clinical trials for endogenous anterior uveitis, of which 106 were exposed to difluprednate. The most common adverse reactions of those exposed to difluprednate occurring in 5-10% of subjects included blurred vision, eye irritation, eye pain, headache, increased IOP, iritis, limbal and conjunctival hyperemia, punctate keratitis, and uveitis. Adverse reactions occurring in 2-5% of subjects included anterior chamber flare, corneal edema, dry eye, iridocyclitis, photophobia, and reduced visual acuity.

  • 8 USE IN SPECIFIC POPULATIONS

    8.1 Pregnancy

    Teratogenic Effects

    Pregnancy Category C. Difluprednate has been shown to be embryotoxic (decrease in embryonic body weight and a delay in embryonic ossification) and teratogenic (cleft palate and skeletal anomalies) when administered subcutaneously to rabbits during organogenesis at a dose of 1-10 mcg/kg/day. The no-observed-effect-level (NOEL) for these effects was 1 mcg/kg/day, and 10 mcg/kg/day was considered to be a teratogenic dose that was concurrently found in the toxic dose range for fetuses and pregnant females. Treatment of rats with 10 mcg/kg/day subcutaneously during organogenesis did not result in any reproductive toxicity, nor was it maternally toxic. At 100 mcg/kg/day after subcutaneous administration in rats, there was a decrease in fetal weights and delay in ossification, and effects on weight gain in the pregnant females. It is difficult to extrapolate these doses of difluprednate to maximum daily human doses of difluprednate, since difluprednate is administered topically with minimal systemic absorption, and difluprednate blood levels were not measured in the reproductive animal studies. However, since use of difluprednate during human pregnancy has not been evaluated and cannot rule out the possibility of harm, difluprednate ophthalmic emulsion should be used during pregnancy only if the potential benefit justifies the potential risk to the embryo or fetus.

    8.3 Nursing Mothers

    It is not known whether topical ophthalmic administration of corticosteroids could result in sufficient systemic absorption to produce detectable quantities in breast milk. Systemically administered corticosteroids appear in human milk and could suppress growth, interfere with endogenous corticosteroid production, or cause other untoward effects. Caution should be exercised when difluprednate ophthalmic emulsion is administered to a nursing woman.

    8.4 Pediatric Use

    Difluprednate was evaluated in a 3-month, multicenter, double-masked trial in 79 pediatric patients (39 difluprednate; 40 prednisolone acetate) 0 to 3 years of age for the treatment of inflammation following cataract surgery. A similar safety profile was observed in pediatric patients comparing difluprednate to prednisolone acetate ophthalmic suspension, 1%.

    8.5 Geriatric Use

    No overall differences in safety or effectiveness have been observed between elderly and younger patients.

  • 11 DESCRIPTION

    Difluprednate ophthalmic emulsion 0.05% is a sterile, topical anti-inflammatory corticosteroid for ophthalmic use. The chemical name is 6α,9difluoro-11β,17,21- trihydroxypregna-1,4-diene-3,20-dione 21-acetate 17-butyrate (CAS number 23674-86-4). Difluprednate is represented by the following structural formula:

    Image

    Difluprednate has a molecular weight of 508.55, and the empirical formula is C27H34F2O7.

    Each mL contains: ACTIVE: difluprednate 0.5 mg (0.05%); INACTIVE: boric acid, castor oil, glycerin, polysorbate 80, water for injection, sodium acetate, edetate disodium, sodium hydroxide (to adjust the pH to 5.2 to 5.8). The emulsion is essentially isotonic with a tonicity of 304 to 411 mOsm/kg. PRESERVATIVE: sorbic acid 0.1%.

  • 12 CLINICAL PHARMACOLOGY

    12.1 Mechanism of Action

    Corticosteroids inhibit the inflammatory response to a variety of inciting agents and may delay or slow healing. They inhibit edema, fibrin deposition, capillary dilation, leukocyte migration, capillary proliferation, fibroblast proliferation, deposition of collagen, and scar formation associated with inflammation. There is no generally accepted explanation for the mechanism of action of ocular corticosteroids. However, corticosteroids are thought to act by the induction of phospholipase A2 inhibitory proteins, collectively called lipocortins. It is postulated that these proteins control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotreines by inhibiting the release of their common precursor arachidonic acid. Arachidonic acid is released from membrane phospholipids by phospholipase A2. Difluprednate is structurally similar to other corticosteroids.

    12.3 Pharmacokinetics

    Difluprednate undergoes deacetylation in vivo to 6α, 9-difluoroprednisolone 17-butyrate (DFB), an active metabolite of difluprednate. Clinical pharmacokinetic studies of difluprednate after repeat ocular instillation of 2 drops of difluprednate (0.01% or 0.05%) four times per day for 7 days showed that DFB levels in blood were below the quantification limit (50 ng/mL) at all time points for all subjects, indicating the systemic absorption of difluprednate after ocular instillation of difluprednate is limited.

  • 13 NONCLINICAL TOXICOLOGY

    13.1 Carcinogenesis, Mutagenesis, and Impairment of Fertility

    Difluprednate was not genotoxic in vitro in the Ames test, and in cultured mammalian cells CHL/IU (a fibroblastic cell line derived from the lungs of newborn female Chinese hamsters). An in vivo micronucleus test of difluprednate in mice was also negative. Treatment of male and female rats with subcutaneous difluprednate up to 10 mcg/kg/day prior to and during mating did not impair fertility in either gender. Long term studies have not been conducted to evaluate the carcinogenic potential of difluprednate.

    13.2 Animal Toxicology and/or Pharmacology

    In multiple studies performed in rodents and non-rodents, subchronic and chronic toxicity tests of difluprednate showed systemic effects such as suppression of body weight gain; a decrease in lymphocyte count; atrophy of the lymphatic glands and adrenal gland; and for local effects, thinning of the skin; all of which were due to the pharmacologic action of the molecule and are well known glucocorticosteroid effects. Most, if not all of these effects were reversible after drug withdrawal. The NOEL for the subchronic and chronic toxicity tests were consistent between species and ranged from 1-1.25 mcg/kg/day.

  • 14 CLINICAL STUDIES

    14.1 Ocular Surgery

    Clinical efficacy was evaluated in 2 randomized, double-masked, placebo-controlled trials in which subjects with an anterior chamber cell grade ≥ "2" (a cell count of 11 or higher) after cataract surgery were assigned to difluprednate or placebo (vehicle) following surgery. One drop of difluprednate or vehicle was self instilled either 2 times per day or 4 times per day for 14 days, beginning the day after surgery. The presence of complete clearing (a cell count of 0) was assessed 3, 8 and 15 days post-surgery using a slit lamp binocular microscope. In the intent-to-treat analyses of both studies, a significant benefit was seen in the 4 times per day (QID) difluprednate-treated group in ocular inflammation, at days 8 and 15, and reduction of pain, at days 3, 8 and 15, when compared with placebo. The consolidated clinical trial results are provided below.

    Image
    Image

    14.2 Endogenous Anterior Uveitis

    Clinical efficacy was evaluated in two randomized, double masked active controlled trials in which patients who presented with endogenous anterior uveitis were treated with either difluprednate 4 times daily or prednisolone acetate ophthalmic suspension, 1%, 8 times daily for 14 days. Both studies demonstrated that difluprednate was equally effective as prednisolone acetate ophthalmic suspension, 1% in treating subjects with endogenous anterior uveitis.

    Mean Change from Baseline in Anterior Chamber Cell Grade*
    Study 1 time point
    		Difluprednate N=57
    		Prednisolone Acetate N=53
    		Difference† (95% CI)
    Baseline
    		 2.6
    		 2.5
    		 0.0 (-0.22, 0.28)
    Day 3
    		 -1.0
    		 -1.0
    		 -0.1 (-0.35, 0.25)
    Day 7
    		 -1.6
    		 -1.5
    		 -0.0 (-0.31, 0.25)
    Day 14
    		 -2.0
    		 -1.8
    		 -0.2 (-0.46, 0.10)
    Day 21
    		 -2.2
    		 -1.9
    		 -0.3 (-0.53, 0.01)
    Day 28
    		 -2.2
    		 -2.1
    		 -0.1 (-0.37, 0.18)
    Day 35
    		 -2.1
    		 -2.0
    		 -0.1 (-0.39, 0.20)
    Day 42
    		 -2.1
    		 -2.1
    		 0.0 (-0.27, 0.34)
    Study 2 time point
    		Difluprednate N=50
    		Prednisolone Acetate N=40
    		Difference† (95% Cl)
    Baseline
    		 2.4
    		 2.4
    		 0.0 (-0.21, 0.29)
    Day 3
    		 -0.9
    		 -0.9
    		 -0.0 (-0.34, 0.25)
    Day 7
    		 -1.7
    		 -1.6
    		 -0.1 (-0.35, 0.21)
    Day 14
    		 -1.9
    		 -1.8
    		 -0.1 (-0.34, 0.20)
    Day 21
    		 -2.0
    		 -2.0
    		 0.0 (-0.25, 0.28)
    Day 28
    		 -2.0
    		 -2.0
    		 0.0 (-0.21, 0.26)
    Day 35
    		 -2.1
    		 -2.0
    		 -0.1 (-0.32, 0.16)
    Day 42
    		 -2.0
    		 -1.9
    		 -0.1 (-0.36, 0.24)
    * with 5 grades: 0 = 0 cells; 1 = 1 to 10 cells; 2 = 11 to 20 cells; 3 = 21 to 50 cells; and 4 = >50 cells
    † adjusted for baseline AC cell grade and study center and based on ITT dataset with LOCF for missing data
  • 16 HOW SUPPLIED/STORAGE AND HANDLING

    Difluprednate ophthalmic emulsion 0.05% is a sterile, white colour homogenous topical ophthalmic emulsion supplied in a white opaque LDPE bottle with a controlled drop tip and a pink cap in the

    following size:

    5 mL in a 5 mL bottle (NDC: 76282-708-50)

    Storage and Handling

    Store at 15-25°C (59-77°F). Do not freeze. Protect from light. When not in use, keep the bottles in the protective carton.

  • 17 PATIENT COUNSELING INFORMATION

    17.1 Risk of Contamination

    This product is sterile when packaged. Advise patients not to allow the dropper tip to touch any surface, as this may contaminate the emulsion.

    Use of the same bottle for both eyes is not recommended with topical eye drops that are used in association with surgery.

    17.2 Risk of Secondary Infection

    If pain develops, or if redness, itching, or inflammation becomes aggravated, advise patients to consult a physician.

    17.3 Contact Lens Wear

    Difluprednate ophthalmic emulsion should not be instilled while wearing contact lenses. Advise patients to remove contact lenses prior to instillation of difluprednate ophthalmic emulsion. The preservative in difluprednate ophthalmic emulsion may be absorbed by soft contact lenses. Lenses may be reinserted after 10 minutes following administration of difluprednate ophthalmic emulsion.

    Manufactured for:

    Exelan Pharmaceuticals, Inc.

    Boca Raton, FL 33432

    Issued 11/2021

  • PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

    NDC: 76282-708-50      Rx Only

    Difluprednate

    Ophthalmic Emulsion

    0.05 %

    FOR OPHTHALMIC

    USE ONLY

    Sterile

    5ml

    EXELAN

    PHARMACEUTICAL INC.

    container label

    image

    NDC: 76282-708-50      Rx Only

    Difluprednate

    Ophthalmic Emulsion

    0.05 %

    FOR OPHTHALMIC

    USE ONLY

    Sterile

    5ml

    Exelan

    Pharmaceuticals, Inc.

    carton label

    image

  • INGREDIENTS AND APPEARANCE
    DIFLUPREDNATE 
    difluprednate emulsion
    Product Information
    Product TypeHUMAN PRESCRIPTION DRUGItem Code (Source)NDC: 76282-708
    Route of AdministrationOPHTHALMIC
    Active Ingredient/Active Moiety
    Ingredient NameBasis of StrengthStrength
    DIFLUPREDNATE (UNII: S8A06QG2QE) (DIFLUPREDNATE - UNII:S8A06QG2QE) DIFLUPREDNATE0.5 mg  in 1 mL
    Inactive Ingredients
    Ingredient NameStrength
    BORIC ACID (UNII: R57ZHV85D4)  
    CASTOR OIL (UNII: D5340Y2I9G)  
    GLYCERIN (UNII: PDC6A3C0OX)  
    POLYSORBATE 80 (UNII: 6OZP39ZG8H)  
    WATER (UNII: 059QF0KO0R)  
    SODIUM HYDROXIDE (UNII: 55X04QC32I)  
    SORBIC ACID (UNII: X045WJ989B)  
    EDETATE DISODIUM (UNII: 7FLD91C86K)  
    SODIUM ACETATE (UNII: 4550K0SC9B)  
    Packaging
    #Item CodePackage DescriptionMarketing Start DateMarketing End Date
    1NDC: 76282-708-501 in 1 CARTON12/10/2021
    15 mL in 1 BOTTLE; Type 0: Not a Combination Product
    Marketing Information
    Marketing CategoryApplication Number or Monograph CitationMarketing Start DateMarketing End Date
    ANDAANDA21177612/10/2021
    Labeler - Exelan Pharmaceuticals, Inc. (967795266)
    Registrant - Cipla USA Inc. (078719707)
    Establishment
    NameAddressID/FEIBusiness Operations
    Farmabios S.p.A.428680078API MANUFACTURE(76282-708)
    • © 2024 FDA.report
    This site is not affiliated with or endorsed by the FDA.